World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 26 June 2023
Main ID:  NCT02924727
Date of registration: 04/10/2016
Prospective Registration: Yes
Primary sponsor: Novartis Pharmaceuticals
Public title: Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI PARADISE-MI
Scientific title: A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an Acute Myocardial Infarction (AMI)
Date of first enrolment: December 9, 2016
Target sample size: 5669
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02924727
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 3
Countries of recruitment
Argentina Australia Austria Belgium Brazil Bulgaria Canada China
Colombia Croatia Czechia Denmark Finland France Germany Greece
Hungary India Israel Italy Korea, Republic of Mexico Netherlands Norway
Peru Philippines Poland Portugal Romania Russian Federation Singapore Slovakia
South Africa Spain Sweden Switzerland Taiwan Thailand Turkey United Kingdom
United States
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Male or female patients = 18 years of age.

2. Diagnosis of spontaneous AMI based on the universal MI definition* with randomization
to occur between 12 hours and 7 days after index event presentation. (*patients with
spontaneous MI event determined to be secondary to another medical condition such as
anemia, hypotension, or arrhythmia OR thought to be caused by coronary vasospasm with
document normal coronary arteries are not eligible; patients with clinical
presentation thought to be related to Takotsubo cardiomyopathy are also not eligible)

3. Evidence of LV systolic dysfunction and/or pulmonary congestion requiring intravenous
treatment associated with the index MI event defined as:

- LVEF =40% after index MI presentation and prior to randomization and/or

- Pulmonary congestion requiring intravenous treatment with diuretics,
vasodilators, vasopressors and/or inotropes, during the index hospitalization

4. At least one of the following 8 risk factors:

- Age = 70 years

- eGFR <60 mL/min/1.73 m^2 based on MDRD formula at screening visit

- Type I or II diabetes mellitus

- Documented history of prior MI

- Atrial fibrillation as noted by ECG, associated with index MI

- LVEF <30% associated with index MI

- Worst Killip class III or IV associated with index MI requiring intravenous
treatment

- STEMI without reperfusion therapy within the first 24 hours after presentation

5. Hemodynamically stable defined as:

- SBP = 100 mmHg at randomization for patients who received ACEi/ARB during the
last 24 hours prior to randomization

- SBP = 110 mmHg at randomization for patients who did not receive ACEi/ARB during
the last 24 hours prior to randomization

- No IV treatment with diuretics, vasodilators, vasopressors and/or inotropes
during the 24 hours prior to randomization

Key Exclusion Criteria:

1. Known history of chronic HF prior to randomization

2. Cardiogenic shock within the last 24 hours prior to randomization

3. Persistent clinical HF at the time of randomization

4. Coronary artery bypass graft (CABG) performed or planned for index MI

5. Clinically significant right ventricular MI as index MI

6. Symptomatic hypotension at screening or randomization

7. Patients with a known history of angioedema

8. Stroke or transient ischemic attack within one month prior to randomization

9. Known or suspected bilateral renal artery stenosis

10. Clinically significant obstructive cardiomyopathy

11. Open-heart surgery performed within one month prior to randomization or planned
cardiac surgery w/in the 3 months prior to randomization

12. eGFR < 30 ml/min/1.73 m^2 as measured by MDRD at screening

13. Serum potassium > 5.2 mmol /L (or equivalent plasma potassium value) at randomization

14. Known hepatic impairment (as evidenced by total bilirubin > 3.0 mg/dL or increased
ammonia levels, if performed), or history of cirrhosis with evidence of portal
hypertension such as esophageal varices

15. Previous use of LCZ696

16. History of malignancy of any organ system (other than localized basal cell carcinoma
of the skin) within the past 3 years with a life expectancy of less than 1year.

17. History of hypersensitivity to the study drugs or drugs of similar chemical classes or
known intolerance or contraindications to study drugs or drugs of similar chemical
classes including ACE inhibitors, ARB or NEP inhibitors

18. Pregnant or nursing women or women of child-bearing potential unless they are using
highly effective methods of contraception



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Acute Myocardial Infarction
Intervention(s)
Drug: LCZ696 (sacubitril/valsartan)
Drug: Placebo of ramipril
Drug: Placebo of LCZ696
Drug: Ramipril
Drug: Valsartan
Drug: Placebo of valsartan
Primary Outcome(s)
Number of Participants With First CEC (Clinical Endpoint Committee) Confirmed Primary Composite Endpoint [Time Frame: From randomization to first occurrence (up to approximately 43 months)]
Secondary Outcome(s)
Total Number of Confirmed Composite Endpoints [Time Frame: Time from randomization to end of study (approximately up to 43 months)]
All-cause Mortality for Full Analysis Set (FAS) [Time Frame: Time from randomization to death (approximately up to 43 months)]
Number of Participants With a Confirmed Composite of HF Hospitalization or Outpatient HF [Time Frame: Time from randomization to first occurrence (approximately up to 43 months)]
Number of Participants With a Confirmed Composite of CV Death or HF Hospitalization [Time Frame: Time from randomization to first occurrence (up to approximately 43 months)]
Number of Participants With a Confirmed Composite of CV Death, Non-fatal Spontaneous Myocardial Infarction or Non-fatal Stroke [Time Frame: Time from randomization to first occurrence (approximately up to 43 months)]
Secondary ID(s)
2016-002154-20
CLCZ696G2301
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 22/06/2023
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02924727
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history